FREFULNA Trademark
Trademark Overview
On Tuesday, December 10, 2024, a trademark application was filed for FREFULNA with the United States Patent and Trademark Office. The USPTO has given the FREFULNA trademark a serial number of 98894275. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, September 29, 2025. This trademark is owned by GlaxoSmithKline Biologicals SA. The FREFULNA trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
General Information
| Serial Number | 98894275 |
| Word Mark | FREFULNA |
| Filing Date | Tuesday, December 10, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, September 29, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 21, 2025 |
Trademark Statements
| Goods and Services | Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, December 10, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | GlaxoSmithKline Biologicals SA |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 33 - NOT AVAILABLE |
| Address | Rixensart B-1330
BE |
Trademark Events
| Event Date | Event Description |
| Tuesday, December 10, 2024 | NEW APPLICATION ENTERED |
| Wednesday, May 28, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, December 10, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, June 2, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Monday, June 2, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, June 2, 2025 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Monday, June 2, 2025 | SUSPENSION LETTER WRITTEN |
| Monday, June 2, 2025 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, September 16, 2025 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Tuesday, September 16, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, September 18, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, September 16, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, June 2, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Monday, June 2, 2025 | EXAMINERS AMENDMENT -WRITTEN |
